文献速递头痛与眩晕

偏头痛患者血浆CGRP水平:一项注册研究

Plasma CGRP Levels in Migraine: A Registry for Migraine Study.
PubMed 文献 · Neurology · 2026-06-12

该横断面观察研究纳入588例偏头痛患者和147名匹配健康对照,采用放射免疫法测定血浆CGRP浓度。结果显示偏头痛患者血浆CGRP中位数低于对照组(125 vs 151 pmol/L,p<0.001),且各亚型、发作期与间歇期及预防用药之间无显著差异。研究提示偏头痛并非以循环CGRP升高为特征,血浆CGRP作为疾病生物标志物的价值有限。

要点

  • 偏头痛患者血浆CGRP中位数低于健康对照(125 vs 151 pmol/L,p<0.001)。
  • CGRP水平在偏头痛各亚型、发作状态及预防用药间均无显著差异。
  • 血浆CGRP不宜作为偏头痛疾病活动度的生物标志物。

核心结论

  • 偏头痛患者血浆CGRP浓度轻度低于健康对照,且不随临床亚型或疾病状态变化。
  • 研究结果挑战了偏头痛以循环CGRP升高为特征的假设,提示血浆CGRP作为疾病生物标志物的效用有限。

研究设计与样本

  • 横断面观察研究,纳入588例偏头痛成人患者(≥18岁,主要为专科诊疗来源)和147名年龄、性别、BMI及样本储存时间1:4匹配的健康对照。
  • 通过肘前静脉采血,采用经验证的高亲和力放射免疫法双份测定血浆CGRP浓度。
  • 主要结局为组间血浆CGRP浓度差异,采用Mann-Whitney U检验比较,回归模型评估临床变量关联。

主要发现

  • 偏头痛患者血浆CGRP中位数(四分位距)为125(68-173)pmol/L,低于对照组的151(118-199)pmol/L,p<0.001。
  • 亚组分析显示发作性vs慢性、有先兆vs无先兆、发作期vs间歇期及预防用药与否各组间均无显著差异(所有p>0.05)。
  • 仅限无头痛患者的敏感性分析证实所有偏头痛亚组血浆CGRP均低于对照(所有p<0.001)。
  • 多变量模型未发现血浆CGRP水平的临床预测因素;样本储存时间与测定水平不相关(Spearman ρ=-0.032;p=0.37)。

临床怎么用

  • 临床不应依据血浆CGRP水平判断偏头痛疾病活动度或选择预防治疗。
  • CGRP作为偏头痛治疗靶点的机制地位不受循环水平影响,但外周CGRP检测无辅助诊断价值。

局限性

  • 横断面设计无法推断因果关系或纵向变化。
  • 患者主要来自专科诊疗,可能存在选择偏倚。
  • 单次采血测量可能无法反映CGRP的动态变化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Calcitonin gene-related peptide (CGRP) plays a central mechanistic role in migraine and is an established drug target. However, it remains unclear whether peripheral plasma CGRP levels meaningfully reflect disease activity. We investigated whether circulating plasma CGRP differs between individuals with migraine and healthy controls and whether concentrations vary across migraine subtypes, clinical status, and preventive treatment use. METHODS: This cross-sectional observational study enrolled adults (≥18 years) with migraine with aura, migraine without aura, or chronic migraine primarily from specialized care. Healthy controls without personal or first-degree family history of primary headache disorders were mainly recruited through web-based advertisement. Venous blood was obtained by antecubital phlebotomy, and plasma CGRP was quantified in duplicate using a validated high-affinity radioimmunoassay. Controls were matched 1:4 to participants with migraine on age, sex, body mass index, and storage duration. The primary outcome was between-group difference in plasma CGRP concentrations. Group comparisons were performed using Mann-Whitney U tests. Regression models were performed to assess associations with clinical variables. RESULTS: A total of 588 participants with migraine and 147 matched controls were analyzed (mean age 43.1 ± 11.9 vs 41.5 ± 11.5 years; 88.8% vs 85.7% female). The median (interquartile range) plasma CGRP concentrations were lower in participants with migraine compared with controls (125 [68-173] vs 151 [118-199] pmol/L; p < 0.001). Subgroup analyses revealed no significant differences across subtypes (episodic vs chronic, with aura vs without aura), ictal vs interictal status, or preventive medication use (all p > 0.05). Sensitivity analyses restricted to headache-free participants confirmed the principal findings, demonstrating lower plasma CGRP concentrations across all migraine subgroups compared with controls (all p < 0.001). Multivariable models identified no clinical predictors of plasma CGRP levels. Sample storage duration did not correlate with measured levels (Spearman ρ = -0.032; p = 0.37). DISCUSSION: Plasma CGRP concentrations were modestly lower in migraine and did not vary by clinical subtype or disease state. These findings challenge the assumption that migraine is characterized by elevated circulating CGRP and suggest limited utility of plasma CGRP as a disease biomarker.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Karlsson WK, Christensen RH, Al-Khazali HM, et al. Plasma CGRP Levels in Migraine: A Registry for Migraine Study. Neurology. 2026. PMID: 42284536. doi:10.1212/WNL.0000000000218152

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。